Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults

Haematologica

Volumn 81, Issue 1, 1996, Pages 20-36

  Bassan, Renato ^a   Lerede, Teresa ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Adult ALL; Management; New options; Recurrence

Indexed keywords

ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CYTARABINE; ETOPOSIDE; GLYCOPROTEIN P; MITOXANTRONE; PODOPHYLLOTOXIN DERIVATIVE; TENIPOSIDE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESISTANCE; HUMAN; MOUSE; NONHUMAN; PRACTICE GUIDELINE; REVIEW; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE MARROW TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MIDDLE AGED; RECURRENCE; RISK FACTORS;

EID: 0030322488     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. Hoelzer D. Treatment of acute lymphoblastic leukemia. Semin Hematol 1994; 31:1-15.
2. Levasseur M, Mung ZT, Jackson GH, et al. Relapse of acute lymphoblastic leukemia 14 years after presentation: use of molecular techniques to confirm true re-emergence. Br J Haematol 1994; 87:437-8.
3. Fière D, Lepage E, Sebban C, et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. J Clin Oncol 1993; 11:1990-2001.
4. Bassan R, Battista R, Rohatiner AZS, et al. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16-year period. Leukemia 1992; 6(suppl 2):186-90.
5. Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of adult lymphoblastic leukemia in adults. Blood 1988; 71:123-31.
6. Mandelli F, Rotoli B, Aloe Spiriti MA, et al. GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. Br J Haematol 1989; 71:377-86.
7. Hussein KK, Dahlberg S, Head D, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood 1989; 73:57-63.
8. Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high-risk acute lymphocytic leukemia. J Clin Oncol 1990; 8:994-1004.
9. Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment with cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized trial by Cancer and Leukemia Group B. J Clin Oncol 1991; 9:2002-15.
10. Omura GA, Raney M. Long-term survival in adult acute lymphoblastic leukemia: follow-up of a Southeastern Cancer Study Group trial. J Clin Oncol 1985; 3:1053-8.
11. Linker CA, Levin LJ, O'Donnel M, Forman SJ, Ries CA. Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood 1991; 78:2814-22.
12. Walters R, Kantarjian HM, Keating MJ, et al. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med 1990; 89:579-87.
13. First MIC Cooperative Study Group. Morphologic, immunologie, and cytogenetic (MIC) working classification of acute lymphoblastic leukemias. Cancer Genetics Cytogenetics 1986; 23:189-97.
14. Raghavachar A, Thiel E, Bartram CR. Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. Blood 1987; 70:1079-83.
15. Chucrallah A, Stass SA, Huh YO, Kantarjian HM. Adult acute lymphoblastic leukemia at relapse: cytogenetic, immunophenotypic, and molecular changes (Abstract). Blood 1994; 84 (suppl 1):307a.
16. Heerema NA, Palmer CG, Weetman R, Bertolone S. Cytogenetic analysis in relapsed childhood acute lymphoblastic leukemia. Leukemia 1992; 6:185-92.
17. Raimondi SC, Pui C-H, Head DR, Rivera GC, Behm FG. Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia. Blood 1993; 82:576-80.
18. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85:1416-34.
19. Uckun FM, Sather H, Reaman G, et al. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia. Blood 1995; 85:873-8.
20. Chiu EKW, Chan LC, Liang R, et al. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect. Leukemia 1994; 8:1469-73.
21. Todeschini G, Meneghini V, Pizzolo G, et al. Relationship between dauonorubicin dosage delivered during induction therapy and outcome in adult acute lymphoblastic leukemia. Leukemia 1994; 8:376-81.
22. Bassan R, Lerede T, Barbui T. Institutional performance and dose intensity as prognostic factors in adult ALL. Leukemia 1995; 9:933-4.
23. Clarkson B, Ellis S, Little C, et al. Acute lymphoblastic leukemia in adults. Semin Oncol 1985; 12:160-79.
24. Foà R, Guarini A, Gansbacher B. IL-2 treatment for cancer: from biology to gene therapy. Br J Cancer 1992; 66:992-8.
25. Attal M, Blaise D, Marrit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia (ALL): a prospective study comparing allo-BMT versus auto-BMT, and testing the impact of IL-2 after auto-BMT. Blood 1994; 84(suppl 1): 251a.
26. Bergamaschi G, Rosti V, Danova M, Lucotti C, Cazzola M. Apoptosis: biological and clinical aspects. Haematologica 1994; 79:86-93.
27. Gale RP, Butturini A. Maintenance chemotherapy and cure of childhood acute lymphoblastic leukaemia. Lancet 1991; 338:1315-8.
28. Greaves M. Stem cell origins of leukemia and curability. Br J Cancer 1993; 67:413-23.
29. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood 1994; 84:2412-21.
30. Hsiao MH, Yu AL, Yeargin J, Ku D, Haas M. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with relapse phase. Blood 1994; 83:2922-30.
31. Smets LA, Van den Berg J, Acton D, Top B, Van Rooij H, Verwijs-Janssen M. BCL-2 expression and mithocondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 1994; 84:1613-9.
32. Smetsers TFCM, Skorski T, van de Locht LTF, et al. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 1994; 8:129-40.
33. Manabe A, Coustan-Smith E, Kumagai M, et al. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia. Blood 1994; 83:1731-7.
34. Hall AG, Cattan AR. Drug resistance mechanisms in leukaemia. Baillière's Clin Haematol 1991; 4:655-81.
35. Savignano C, Geromin A, Michieli M, et al. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. Haematologica 1993; 78:261-3.
36. Marie JP, Zittoun R, Sikic B. Multidrug resistance (mdr-1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78:586-92.
37. Goasguen JE, Dossot J-M, Fardel O, et al. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993; 81:2394.
38. Dalton WS, List A, Grogan TM, Miller TP, Scheper RG, Salmon SE. P-glycoprotein and non-P-glycoprotein mediated multidrug resistance in hematopoietic malignancies (Abstr.). Leukemia 1995; 9:534.
39. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr 1, mrp, topoisomerase IIa/b, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 1995; 89:356-63.
40. Schneider E, Cowan KH, Bader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85:186-93.
41. Walker A, Dive C, Radford J, Hickman JA. Apoptosis in leukaemia and lymphoma (Abstr.). Leukemia 1995, 9:529.
42. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327-36.
43. Hongo T, Fujii Y, Igarashi Y. An in vitro chemosensitivity test for the screening of anti-cancer drugs in childhood leukemia. Cancer 1990, 65:1263-72.
44. Weisenthal LM, Marsden JA, Dill PL, Macaluso CK. A novel dye exclusion method for testing in vitro chemosensivity of human tumors. Cancer Res 1983; 43:749-57.
45. Lacombe F, Belloc F, Dumain P, et al. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood 1994; 84:716-23.
46. Slapak CA, Mizunuma N, Kufe D. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood 1994; 84:3113-21.
47. List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993; 11:1652-60.
48. Ross DD, Wooten PJ, Tong Y, et al. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and cremophor EL. Blood 1994; 83: 1337-47.
49. Laredo J, Huynh A, Muller C, et al. Effect of the protein kinase C inhibitor staurosporine on chemosensitivity to daunorubicin of normal and leukemic fresh myeloid cells. Blood 1994; 84:229-37.
50. Moscow JA, Schneider E, Cowan KA. Multidrug resistance. In: Pinedo HM, Longo DL, Chabner BA, eds. Cancer chemotherapy and biological response modifiers. Annual 14. Amsterdam: Elsevier 1993:98-117.
51. Jaffrézou J-P, Sikic BI, Laurent G. Cyclosporin A and cyclosporin SDZ PSC 833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood 1994; 83: 482-9.
52. Welborn JL. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults. Am J Hematol 1994; 45:341-4.
53. Slevin ML, Shannon MS, Prentice HG, Goldman AJ, Lister TA. A phase I and II study of m-AMSA in acute leukemia. Cancer Chemother Pharmacol 1981; 6:137-40.
54. Arlin ZA, Fanucchi MP, Gee TS, et al. Treatment of refractory adult acute lymphoblastic leukemia (ALL) with 4′ (9-acridinylamino) methanesulfon-M-anisidide (AMSA). Blood 1982; 60:1224-6.
55. Paciucci PA, Cuttner J, Holland JF. Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia. Semin Oncol 1984; 11(suppl 3): 36-40.
56. Carella AM, Santini G, Martinengo M, et al. 4-demethoxydaunorubicin (idarubicin) in refractory or relapsed acute leukemias. Cancer 1985; 55:1452-4.
57. Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood 1982; 60: 484-90.
58. Bickers J, Benjamin R, Wilson H, Eyre H, Hewlett J, Mc Credie KB. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: a Southwest Oncology Group study. Cancer Treat Rep 1981; 65:427-30.
59. Bezwoda WR, Bernasconi C, Hutchinson RM, Winfield DA, de Bock R, Mandelli F. Mitoxantrone for refractory and relapsed acute leukemia. Cancer 1990; 66:418-22.
60. Elias L, Shaw MT, Raab SO. Reinduction therapy for adult acute leukemia with adriamycin, vincristine and prednisone: a Southwest Oncology Group study. Cancer Treat Rep 1979; 63:1413-5.
61. Woodruff RK, Lister TA, Paxton AM, et al. Combination chemotherapy for hematological relapse in adult acute lymphoblastic leukemia. Am J Hematol 1978; 4:173-7.
62. Paciucci PA, Keaveney C, Cuttner J, Holland JF. Mitoxantrone, vincristine and prednisone in adults with relapsed or primarily refractory acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase cronic myelocytic leukemia. Cancer Res 1987; 47:5234-7.
63. Kantarajian HM, Walters RS, Keating MJ, Barlogie B, Mc Credie KB, Freireich EJ. Experience with vincristine, doxorubicin, dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer 1989; 64:16-22.
64. Bassan R, Cornelli PE, Battista R, et al. Intensive retreatment of adults and children with acute lymphoblastic leukemia. Hematol Oncol 1992; 10:105-10.
65. Bassan R, Battista R, Viero P, et al. Intensive therapy for adult lymphoblastic leukemia: preliminary results of the idarubicin/vincristine/L-asparaginase/prednisolone regimen. Semin Oncol 1993; 20(Suppl 8):39-46.
66. Early AP, Preisler HD, Gottlieb AJ, Lanchant NA. Treatment of refractory adult acute lymphocytic leukaemia and acute undifferentiated leukaemia with an anthracycline antibiotic and cytosine arabinoside. Br J Haematol 1981; 48:369-75.
67. Liso V, Specchia G, Pavone V, Capalbo S, Dione R. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia. Acta Haematol 1990; 83:116-9.
68. Rowe JM, Chang AYC, Bennet JM. Refractory acute lymphocytic leukemia: response to aclacinomycin A and VP-16-213. Hematol Oncol 1989; 7:405-10.
69. Yap B-S, Mc Credie KB. L-asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep 1981;65(suppl 1):83-7.
70. Esterhay RJ, Wiernik PH, Grove WR, Markus SD, Wesley MN. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia. Blood 1982; 59:334-45.
71. Morra E, Lazzarino M, Alessandrino EP, Inverardi D, Canevari A, Bernasconi C. VP 16-213 and cytosine-arabinoside combination chemotherapy for refractory acute lymphoblastic leukemia in adults. Eur J Cancer Clin Oncol 1984; 20: 1471-5.
72. Sanz GF, Sanz MA, Rafeeas FJ, Martinez JA, Martin-Aragones G, Marty ML. Teniposide and cytarabine combination chemotherapy in treatment of relapsed adolescent and acute lymphoblastic leukemia. Cancer Treat Rep 1986; 70:1321-3.
73. Terebelo HR, Anderson K, Wiernik PH, et al. Therapy of refractory adult acute lymphoblastic leukemia with vin-cristine and prednisone plus tandem methotrexate and L-asparaginase: results of a Cancer Leukemia Group B study. Am J Clin Oncol 1986; 9:411-5.
74. Lee EJ, Reck K, Carter C, Hodges S, Schiffer CA. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia. Leukemia 1993; 7:1500-3.
75. Ryan DH, Bickers JN, Vial RH, et al. Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: a Southewest Oncology Group pilot study. Cancer Treat Rep 1980; 64:869-72.
76. Solidoro A, Otero J, Vallejios C, et al. Intermittent continuous iv infusion of high-dose cyclophosphamide for remission induction in acute lymphocytic leukemia. Cancer Treat Rep 1981; 65:213-8.
77. Timonen TTT. Relapse of acute lymphoblastic leukemia treated with ifosfamide combination chemotherapy. Cancer Treat Rev 1983; 10(suppl A):145-50.
78. Rudnik SA, Cadman EC, Capizzi RL, Skeel RT, Bertino JR, McIntosh S. High dose cytosine arabinoside (HDARA-C) in refractory acute leukemia. Cancer 1979; 44:1189-93.
79. Early AP, Preisler HD, Higby DJ, et al. High-dose cytosine arabinoside: clinical response to therapy in acute leukemia. Med Ped Oncol 1982; 12:(Suppl 1)239-50.
80. Febres R, Flessa HC, Martelo OJ, et al. Efficacy of high dose cytosine arabinoside in refractory adult leukemia (Abstract). Proc Am Soc Clin Oncol 1982; 1:128.
81. Willemze R, Zwaan FE, Colpin G, Keuning JJ. High dose cytosine arabinoside in the management of refractory acute leukemia. Scand J Haematol 1982; 29:141-6.
82. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Kanares C, Herzig GP. High dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62:361-9.
83. Rohatiner AZS, Slevin ML, Dhaliwal HS, Malpas JS, Lister TA. High-dose cytosine arabinoside: response to therapy in acute leukemia and non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 1984; 12:90-3.
84. Keating MJ, Estey E, Plunkett W, et al. Evolution of clinical studies with high-dose cytosine arabinoside at the MD Anderson Hospital. Semin Oncol 1985; 12(suppl 3):98-104.
85. Takaku F, Urabe A, Mizoguchi H, et al. High-dose cytosine arabinoside in the treatment of resistant acute leukemia. Semin Oncol 1985; 12(suppl 3):144-50.
86. Kantarjian HM, Estey EH, Plunkett W, et al. Phase I-II clinical and pharmacological studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 1986; 81:387-94.
87. Barnett MJ, Rohatiner AZS, Ganesan TS, et al. A phase II study of high-dose cytosine in the treatment of acute leukemia in adults. Cancer Chemother Pharmacol 1987; 19: 169-71.
88. Amadori S, Papa G, Avvisati G, et al. Sequential combination of high-dose Ara-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma. Leuk Res 1984; 8:729-35.
89. Capizzi RL, Poole MR, Cooper MR, et al. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase. Blood 1984; 63:694-700.
90. Gore M, Powles R, Lakhani A, et al. Treatment of relapsed and refractory acute leukemia with high-dose cytosine arabinoside and etoposide. Cancer Chemother Pharmacol 1989; 23:373-6.
91. Whelan IS, Davis CL, Rohatiner AZS, et al. Etoposide in combination with intermediate dose cytosine arabinoside (IDAARAC) given with the intention of further myeloablative therapy for the treatment of refractory or recurrent hematological malignancy. Hematol Oncol 1992; 10:87-94.
92. Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukemia in children and adults: the GIMEMA/AIEOP experience. Br J Haematol 1994, 86:55-61.
93. Berman E, Raymond V, Gee T, et al. Idarubicin in acute leukemia: results of studies at the Memorial Sloan-Kettering Cancer Center. Semin Oncol 1989; 16(suppl 2):30-4.
94. Carella AM, Pungolino E, Piatti G, et al. Idarubicin in combination with intermediate-dose cytarabine in the treatment of refractory or relapsed acute leukemias. Eur J Haematol 1989; 43:309-13.
95. Hiddemann W, Kreutzmann H, Straif K, et al. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia. Semin Oncol 1987; 14(suppl 1):73-7.
96. Lejeune C, Tubiana K, Gaustaut GA, et al. High-dose cytosine arabinoside and mitoxantrone in previously-treated acute leukemia patients. Eur J Hematol 1990; 44:240-3.
97. Kantarjian HM, Walters RS, Keating MJ, et al. Mitoxantrone and high-dose cytosine arabinoside for treatment of refractory acute lymphocytic leukemia. Cancer 1990; 65:5-8.
98. Hiddemann W, Buchner T, Heil G, et al. Treatment of refractory acute lymphoblastic leukemia in adults with high-dose cytosine arabinoside and mitoxantrone (HAM). Leukemia 1990; 4:637-40.
99. Feldman E, Zorsky P, Armentrout S, et al. Phase I trial short course high-dose mitoxantrone in combination with high-dose cytarabine (HIDAC) in patients (pts) with acute leukemia and blastic chronic myelogenous leukemia (BLCML) (Abstract). Blood 1990; 76(suppl 1):269a.
100. Rozmylowicz T, Palynyczko G, Matur J, et al. Mitoxantrone in the treatment of refractory acute leukemias (Abstract). Blood 1990; 76(suppl 1):315a.
101. Arlin ZA, Feldman EJ, Finger LR, et al. Short course mitoxantrone with high-dose cytarabine is effective therapy for adult lymphoblastic leukemia. Leukemia 1991; 5:712-4.
102. Kantarjian HM, Estey EH, O'Brien S, et al. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood 1992; 79:876-81.
103. Marit G, Cony P, Duclos F, et al. Treatment of relapsed or refractory acute leukemia: comparison of two different regimens. Hämatol Bluttransfus 1990; 33:614-8.
104. Willemze R, Peters WG, van Hennik MB, et al. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukemia and lymphoblastic non-Hodgkin's lymphoma. Scand J Haematol 1985; 34:83-7.
105. Zittoun R, Bury J, Strykmans P, et al. Amsacrine with high-dose cytarabine in acute leukemia. Cancer Treat Rep 1985, 69:1447-8.
106. Arlin ZA, Feldman E, Kempin S, et al. Amsacrine with high dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults. Blood 1988; 72:433-5.
107. Peters WG, Willemze R, Colly LP. Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic non-Hodgkin's lymphoma: the Leyden experience and review of the literature. Semin Oncol 1987; 14(suppl 1):86-91.
108. Willemze R, Peters WG, Colly LP. Short term intensive treatment (VAAP) of adult lymphoblastic leukemia and lymphoblastic lymphoma. Eur J Haematol 1988; 41:489-95.
109. Milpied N, Gisselbrecht C, Harousseau JL, et al. Successful treatment of acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone and etoposide (PAME) chemotherapy. Cancer 1990; 66:627-31.
110. Freund M, Diedrich H, Ganser A, et al. Treatment of relapsed or refractory adult acute lymphocytic leukemia. Cancer 1992; 69:709-17.
111. Dinsmore R, Kirkpatrick D, Flomenberg N, Gulati S, Shank B, O'Reilly RJ. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: the importance of early transplantation. Transplant Proc 1983; 15:1397-400.
112. Blume KG, Forman SJ, Krance RA, Henke M, Findley DO, Hill LR. Bone marrow transplantation for acute leukemia. Hämatol Bluttransfus 1985, 29:39-41.
113. Van Lint M, Bacigalupo A, Frassoni F, et al. Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL) in remission. Haematologica 1986; 71:135-8.
114. Herzig RH, Barret AJ, Gluckman E, et al. Bone marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet 1987; i:786-8.
115. Kersey JH, Weisdorf D, Nesbit ME, et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. N Engl J Med 1987; 317:461-7.
116. Kersey JH, Weisdorf D, Uckun F, et al. Allogeneic and autologous bone marrow transplantation for high risk acute lymphoblastic leukemia. Leukemia 1992; 6(suppl 2):191-2.
117. Gratwhol A, Hermans J, Barrett AJ, et al. Allogeneic bone marrow transplantation for leukaemia in Europe: report from the Working Party on Leukaemia European Group for Bone Marrow Transplantation. Lancet 1988; i:1379-82.
118. Barret AJ, Horowitz MM, Gale RP, et al. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. Blood 1989; 74:862-71.
119. Wingard JR, Piantadosi S, Santos GW, et al. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. J Clin Oncol 1990; 8:820-30.
120. Doney K, Fisher LD, Appelbaum FR, et al. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. Bone Marrow Transplant 1991; 7:453-9.
121. Buckner CD, Doney K, Sanders J, Petersen F, Appelbaum F. Marrow transplantation for patients with acute lymphoblastic leukemia: the Seattle experience. Leukemia 1992; 6(suppl 2):193-5.
122. Bortin M, Barret AJ, Horowitz MM, Gale RP, Sobocinski KA, Rimm AA. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: a report from the IBMTR. Leukemia 1992; 6(suppl 2): 196-7.
123. Copelan EA, Biggs JC, Avalos BR, et al. Radiation free preparation for allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia. J Clin Oncol 1992; 10: 237-42.
124. Weyman C, Graham-Pole J, Emerson S, et al. Use of cytosine arabinoside and total body irradiation as conditioning for allogeneic marrow transplantation in patients with acute lymphoblastic leukemia: a multicenter survey. Bone Marrow Transplant 1993; 11:43-50.
125. Barret AJ. Bone marrow transplantation for acute lymphoblastic leukaemia. Bailliere's Clin Haematol 1994; 7:377-401.
126. Chao NJ, Forman SJ. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia. In: Forman SJ, Blume KJ, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific Publ. 1994:618-39.
127. Fleming DR, Hensle-Downey PJ, Harder EJ, et al. Partially matched related donor (PMRD) allogeneic bone marrow transplantation (BMT) in recurrent acute lymphoblastic leukemia (ALL) (Abstract). Blood 1994; 84(suppl 1):214a.
128. Busca A, Anasetti C, Anderson G, et al. Unrelated donor or aulologous marrow transplantation for treatment of acute leukemia. Blood 1994; 83:3077-84.
129. Mrsic M, Horowitz MM, Atkinson K, et al. Second HLA-identical sibling transplants for leukemia recurrence. Bone Marrow Transplant 1992; 9:269-75.
130. Uckun FM, Kersey JH, Haake R, et al. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med 1993; 329:1296-301.
131. Rizzoli V, Mangoni L, Carella AM, et al. Drug-mediated marrow purging: maphosphamide in adult acute leukemia in remission. The experience of the Italian Study Group. Bone Marrow Transplant 1989;4(suppl 1):190-4.
132. Simonsson B, Burnett AK, Prentice HG, et al. Autologous bone marrow transplantation with monoclonal antibody purged marrow for high risk acute lymphoblastic leukemia. Leukemia 1989; 3:631-6.
133. Soiffer RJ, Roy DC, Gonin R, et al. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant 1993; 12:243-51.
134. Doney K, Buckner CD, Fisher L, et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1993; 12:315-21.
135. Sierra J, Granena A, Garcia J, et al. Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients. Bone Marrow Transplant 1993; 12:517-23.
136. Carella AM, Marmont AM. Autologous bone marrow transplantation for acute lymphoblastic leukaemia. Bailliere's Clin Haematol 1994; 7:403-19.
137. Juttner CA, Fibbe WE, Nemunaitis J, Kanz I, Gianni AM. Blood cell transplantation: report from an International Consensus Meeting. Bone Marrow Transplant 1994; 14:689-93.
138. Negrin RS, Kusnierz-Glaz CR, Still BJ, Blume KG, Strober S. Minimum number of mobilized peripheral blood CD34: cells required for rapid trilineage engraftment. Bone Marrow Transplant 1994; 14(suppl 3):S87.
139. Mijovic A, Mufti GJ. Do CD34 cell counts predict haematopoietic recovery after autologous blood stem cell transplantation (ABSCT)? Br J Haematol 1995; 89:226.
140. Carlo Stella C, Cazzola M, De Fabritiis P, et al. CD-34-positive cells: biology and clinical relevance. Haematologica 1995; 80:367-87.
141. Martin H, Hoelzer D, Atta J, Eslner S, Claudé R, Bruecher J. Autologous bone marrow transplantation in PH-positive/BCR-ABL positive acute lymphoblastic leukemia (Abstract). Blood 1993; 82(suppl 1):167a.
142. Van Rhee F, Marks DI, Lin F, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9:329-35.
143. Carella AM, Frassoni F, Pollicardo N, et al. Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. Br J Haematol 1995; 89:535-8.
144. Seriu T, Yokota S, Nakao M, et al. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia 1995; 9:615-23.
145. Graham-Pole J. Treating acute lymphoblastic leukaemia after relapse: bone marrow transplantation or not? Lancet 1989; ii: 1517-8.
146. Wolfrom C, Hartmann R, Fengler R, Brühmüller S, Ingwersen A, Henze G. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia. J Clin Oncol 1993; 11:827-33.
147. Bertino JR, Göker E, Kheradpour A, Trippett T, LaCerda J, Waltham M. Clinical relevance of mechanisms of methotrexate resistance (Abstract). Leukemia 1995; 9:532.
148. Lacerda JF, Goker E, Kheradpour A, et al. Selective treatment of SCID mice bearing methotrexate-transport-resistant human acute lymphoblastic leukemia tumors with trimetrexate and leucovorin protection. Blood 1995; 85:2675-9.
149. Uckun FM, Stewart CF, Reaman G, et al. in vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 1995; 85:2817-28.
150. Gorin NC, Lopez M, Laporte J, et al. Preparation and successful engraftment of purified CD34: bone marrow progenitor cells in patients with non-Hodgkin's lymphoma. Blood 1995; 85:1647-54.
151. Trowell OA. The sensivity of lymphocytes to ionizing radiation. J Pathol 1952; 64:687-91.
152. Sellins KS, Cohen JJ. Gene induction by γ-irradiation leads to DNA fragmentation in lymphocytes. J Immunol 1987; 139: 3199-206.
153. Sutton L, Kuentz M, Cordonnier C, et al. Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation modalities. Bone Marrow Transplant 1993; 12: 583-9.
154. Brochstein JA, Kernan NA, Groshen S, et al. Allogeneic marrow transplantation after hyperfractionated total body irradiation and cyclophosphamide in children with acute leukaemia. N Engl J Med 1987; 317:1618-24.
155. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77:1660-5.
156. Shank B. Radiotherapeutic principles of bone marrow transplantation. In: Forman SJ, Blume KJ, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell Scientific Publ. 1994:96-113.
157. Uckun FM, Ramsay KC, Waddick KG, et al. In vitro and in vivo radiation resistance associated with CD3 surface antigen expression in T-lineage acute lymphoblastic leukemia. Blood 1991; 78:2945-55.
158. Uckun FM, Song CW. Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 1993; 81:1323-32.
159. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122-31.
160. Krance RA, Forman SJ, Blume KG. Total body irradiation and high-dose teniposide: a pilot study in bone marrow transplantation for patients with relapsed acute lymphoblastic leukemia. Cancer Treat Rep 1987; 71:645-7.
161. Blume KG, Forman SJ, O'Donnell MR, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987; 69:1015-20.
162. Slevin ML, Piall EM, Aherne GW, Harvey VJ, Johnston A, Lister TA. Effect of dose and schedule of pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid. J Clin Oncol 1983; 1:546.
163. Rohatiner AZS, Bassan R, Battista R, et al. High dose cytosine arabinoside in the initial treatment of adults with acute lymphoblastic leukaemia. Br J Cancer 1990, 62:454-8.
164. Linker C, Ries CA, Damon LE, Rugo HS, Wolf JL. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81:311-8.
165. Biaise D, Maraninchi D, Archimbaud E, et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as a preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79:2578-82.
166. Ringdén O, Labopin M, Mandelli F, et al. A comparison of busulfan vs. total body irradiation combined with cyclophosphamide as conditioning for autograft and allograft bone marrow transplantation in patients with acute leukemia (Abstract). Bone Marrow Transplant 1995; 15(Suppl 2):S69.
167. Henze G, Agthe AG, Neuendank A, et al. Tailored therapy for relapsed or refractory childhood acute lymphoblastic leukemia (Abstract). Leukemia 1995; 9:538.
168. Jiang XR, Kelsey SM, Wu YL, Newland AC. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833. Br J Haematol 1995; 90:375-83.
169. Gonzalez O, Colombo T, Defusco M, Imperatori L, Zucchetti M, D'Incalci M. Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. Cancer Chemother Pharmacol 1995; 36:335-40.
170. Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia 1995; 9:815-20.
171. de Fabritiis P, Calabretta B. Antisense oligodeoxynucleotides for the treatment of chronic myelogenous leukemia: are they still a promise? Haematologica 1995; 80:295-9.
172. Beaujean F, Bernaudin F, Kuentz M, et al. Successful engraftment after autologous transplantation of 10-day cultured bone marrow activated by interleukin 2 in patients with acute lymphoblastic leukemia. Bone Marrow Transplant 1995; 15: 691-6.